# Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder

> **NCT00003452** · PHASE2 · TERMINATED · sponsor: **Burzynski Research Institute** · enrollment: 4 (actual)

## Conditions studied

- Stage IV Bladder Cancer

## Interventions

- **DRUG:** Antineoplaston therapy (Atengenal + Astugenal)

## Key facts

- **NCT ID:** NCT00003452
- **Lead sponsor:** Burzynski Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1996-05-06
- **Primary completion:** 1998-05-04
- **Final completion:** 1998-05-04
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** slow enrollment
- **Last updated:** 2017-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003452, "Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00003452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*